SUTRO BIOPHARMA

Company snapshot

Sutro Biopharma, Inc. is a [publicly traded](en.wikipedia.org/wiki/Public_company) [biotechnology](en.wikipedia.org/wiki/Biotechnology) company headquartered in [South San Francisco](en.wikipedia.org/wiki/South_San_Francisc), California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary [cell-free protein synthesis](en.wikipedia.org/wiki/Cell-free_protein_

• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 34 US patent(s) indexed to this assignee profile.
• 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SUTRO BIOPHARMA. Not investment advice.

• Presentation Jun 22, 2026
  Initial Clinical Data from Sutro Biopharma Pipeline
• Congress Jun 22, 2026
  RESI San Diego

• Peer + 0 momentum

  Solid Biosciences

  TA overlap score 23.2

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for SUTRO BIOPHARMA.

1. Jun 8, 2026 Clinical update

   STRO-002-GM3 — Phase 2

2. Jun 8, 2026 Clinical update

   STRO-002-GM2 — Phase 1

3. Jun 8, 2026 Clinical update

   REFRaME-P1 — Phase 2

4. Jun 5, 2026 Clinical update

   STRO-004 — Phase 1

5. Jun 5, 2026 Clinical update

   STRO-002 — Phase 1

View all clinical trial activity →

• What is SUTRO BIOPHARMA?

  SUTRO BIOPHARMA is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker STRO. Primary therapeutic focus areas include Acute Myeloid Leukemia (AML), Ovarian Cancer, Lung Cancer, B-cell Lymphoma, Neoplasm Malignant. NovaPharmaNews links 1

• Is SUTRO BIOPHARMA publicly traded?

  Yes. SUTRO BIOPHARMA is listed with ticker STRO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SUTRO BIOPHARMA develop or market?

  We link 21 drug profile(s) where SUTRO BIOPHARMA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sutro-biopharma-inc#company-drugs.

• What are the latest developments for SUTRO BIOPHARMA?

  In the last 12 months our linked public records show 10 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does SUTRO BIOPHARMA focus on?

  SUTRO BIOPHARMA focuses on Acute Myeloid Leukemia (AML), Ovarian Cancer, Lung Cancer based on our analysis of their pipeline programs and drug development activities.